Inventiva (NASDAQ:IVA) Earns “Buy” Rating from HC Wainwright

Inventiva (NASDAQ:IVAGet Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $22.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus reduced their price target on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Lifesci Capital reissued an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Eight analysts have rated the stock with a buy rating, Based on data from, the company has an average rating of “Buy” and an average target price of $15.67.

Get Our Latest Report on IVA

Inventiva Price Performance

Shares of IVA opened at $3.63 on Monday. Inventiva has a 1-year low of $2.22 and a 1-year high of $5.05. The firm has a fifty day moving average price of $3.72 and a 200 day moving average price of $3.98.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IVA. Commonwealth Equity Services LLC acquired a new position in shares of Inventiva during the first quarter worth about $51,000. Citigroup Inc. increased its stake in shares of Inventiva by 91.7% during the first quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock worth $84,000 after acquiring an additional 11,000 shares during the period. Finally, Morgan Stanley increased its stake in shares of Inventiva by 300.0% during the fourth quarter. Morgan Stanley now owns 6,000 shares of the company’s stock worth $27,000 after acquiring an additional 4,500 shares during the period. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

(Get Free Report)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.

Read More

Analyst Recommendations for Inventiva (NASDAQ:IVA)

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with's FREE daily email newsletter.